Quadritherapy, compared with carboplatin–paclitaxel–bevacizumab, respectively, obtained a significant PFS benefit (8.3 vs 6.8 months), and an OS gain (19.8 vs 14.9 months).[38] That benefit was observed regardless of the tumor cell or inflammatory cell (IC) PD-L1–expression level, even when those cells were PD-L1–negative and was even better for patients with liver metastases. This evidence concerns the gene CD274 and neoplasm.